4-oxo-4-(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)butanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-oxo-4-(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)butanoic acid
• 英文别名: oxo-4-(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)butanoic acid；4-Oxo-4-(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)butanoic acid；4-oxo-4-[4-[2-(trifluoromethyl)phenyl]piperidin-1-yl]butanoic acid
• 化学式: C₁₆H₁₈F₃NO₃
• 分子量: 329.319
• InChiKey: KULRRGIAQANESH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  邻溴三氟甲苯 在 盐酸 、 正丁基锂 、 氯化亚砜 、 palladium 10% on activated carbon 、 甲酸铵 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 10.17h， 生成 4-oxo-4-(4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)butanoic acid
  参考文献：
  名称：

  [EN] 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE
  [FR] 4-PHÉNYLPIPÉRIDINES, LEUR PRÉPARATION ET LEUR UTILISATION

  摘要：

  本发明提供一种具有以下结构的化合物：(结构表示)其中R1、R2、R3、R4和R5分别独立地为H、卤素、CF3或C1-C4烷基；R6为H、OH或卤素；B为取代或未取代的杂环、吡啶并[1,2-a]嘧啶、吡唑并[1,2-a]嘧啶、噻二唑或三唑，其中该杂环不是氯取代的吲哚；当取代时，吡唑除三氟甲基外还取代其他官能团，或其药学上可接受的盐。

  公开号：

  WO2014152013A1

文献信息

• 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE
  申请人：PETRUKHIN Konstantin

  公开号：US20160046648A1

  公开（公告）日：2016-02-18

  The present invention provides a compound having the structure: (structurally represented) wherein R 1 , R 2 , R 3 , R 4 , and R 5 are each independently H, halogen, CF 3 or C 1 -C 4 alkyl; R 6 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterobicycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种化合物，其结构为：（结构式表示），其中R1、R2、R3、R4和R5各自独立地为H、卤素、CF3或C1-C4烷基；R6为H、OH或卤素；B为取代或未取代杂环、吡嗪、吡唑、吡嗪、噻二唑或三唑，其中杂环不是氯取代的吲哚；当吡唑取代时，取代基不是三氟甲基，或其药学上可接受的盐。
• 4-phenylpiperidines, their preparation and use
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US10273243B2

  公开（公告）日：2019-04-30

  The present invention provides a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterobicycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有以下结构的化合物：(结构表示），其中 R1、R2、R3、R4 和 R5 各自独立地为 H、卤素、CF3 或 C1-C4 烷基；R6 为 H、OH 或卤素；B 为取代或未取代的杂环、哒嗪、吡唑、吡嗪、噻二唑或三唑，其中杂环为氯取代的吲哚以外的杂环；吡唑取代时为三氟甲基以外的取代基，或其药学上可接受的盐。
• Design, Synthesis, and Evaluation of Nonretinoid Retinol Binding Protein 4 Antagonists for the Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease
  作者：Christopher L. Cioffi、Nicoleta Dobri、Emily E. Freeman、Michael P. Conlon、Ping Chen、Douglas G. Stafford、Daniel M. C. Schwarz、Kathy C. Golden、Lei Zhu、Douglas B. Kitchen、Keith D. Barnes、Boglarka Racz、Qiong Qin、Enrique Michelotti、Charles L. Cywin、William H. Martin、Paul G. Pearson、Graham Johnson、Konstantin Petrukhin

  DOI：10.1021/jm5010013

  日期：2014.9.25

  Accumulation of lipofuscin in the retina is associated with pathogenesis of atrophic age-related macular degeneration and Stargardt disease. Lipofuscin bisretinoids (exemplified by N-retinylidene-N-retinylethanolamine) seem to mediate lipofuscin toxicity. Synthesis of lipofuscin bisretinoids depends on the influx of retinol from serum to the retina. Compounds antagonizing the retinol-dependent interaction of retinol-binding protein 4 (RBP4) with transthyretin in the serum would reduce serum RBP4 and retinol and inhibit bisretinoid formation. We recently showed that A1120 (3), a potent carboxylic acid based RBP4 antagonist, can significantly reduce lipofuscin bisretinoid formation in the retinas of Abca4(-/-). mice. As part of the NIH Blueprint Neurotherapeutics Network project we undertook the in vitro exploration to identify novel conformationally flexible and constrained RBP4 antagonists with improved potency and metabolic stability. We also demonstrate that upon acute and chronic dosing in rats, 43, a potent cyclopentyl fused pyrrolidine antagonist, reduced circulating plasma RBP4 protein levels by approximately 60%.